ERBB2 and neoplasm: A total of 46.7% of the patients had ER+/PR+/HER2− tumours, which is the most common subtype, followed by ER+/PR−/HER2− occurring in 20% of the patients, ER+/PR+/HER2+ and ER+/PR−/HER2+ occurring in 13.3% of the patients each, and triple-negative breast cancer (ER−/PR−/HER2−) diagnosed in 6.7% of the patients.